Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 3/20 | 0.43 |
| ▸ | BRD4 | O60885 | 2/20 | 0.43 |
| ▸ | BRAF | P15056 | 1/20 | 0.41 |
| ▸ | LIMK2 | P53671 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | RHOA | P61586 | 2/20 | 0.36 |
| ▸ | GSK3B | P49841 | 3/20 | 0.35 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.35 |
| ▸ | WNT1 | P04628 | 2/20 | 0.35 |
| ▸ | CCR3 | P51677 | 1/20 | 0.34 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.34 |
| ▸ | ATR | Q13535 | 1/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | NCF1 | P14598 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16776108 | 0.86 | CREBBP (0.45) | CREBBPBRD4BRAFLIMK2CNR1 | |
| SCHEMBL19670284 | 0.86 | BRAF (0.41) | CREBBPBRD4BRAFLIMK2CNR1 | |
| SCHEMBL16775979 | 0.84 | CREBBP (0.44) | CREBBPBRD4BRAFLIMK2CNR1 | |
| SCHEMBL16776407 | 0.83 | CREBBP (0.44) | CREBBPBRD4BRAFLIMK2RHOA | |
| SCHEMBL16776047 | 0.82 | KARS1 (0.36) | GSK3BDYRK1AWNT1ATRSMN1; SMN2 | |
| SCHEMBL16776139 | 0.82 | KARS1 (0.36) | GSK3BDYRK1AWNT1ATRSMN1; SMN2 | |
| SCHEMBL19365543 | 0.81 | BRAF (0.43) | CREBBPBRD4BRAFLIMK2CNR1 | |
| SCHEMBL16776123 | 0.81 | ABL1 (0.38) | GSK3BDYRK1ASMN1; SMN2 | |
| SCHEMBL17624674 | 0.80 | BRAF (0.41) | CREBBPBRD4BRAFLIMK2CNR1 | |
| SCHEMBL16785510 | 0.80 | BRAF (0.41) | CREBBPBRD4BRAFLIMK2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | GLAXOSMITHKLINE LLC | 2015-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150152108-A1 | SUBSTITUTED BRIDGED UREA ANALOGS AS SIRTUIN MODULATORS | SIRT1, SIRT3, SIRT2 | CREBBP 528/4885BRD4 180/4885BRAF 3419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.